- ImmuPharma said Thursday talks were ongoing with potential partners to bring its Lupus treatment to market.

ImmuPharma said it continued to look at opportunities, which over the longer term have the potential of bringing its Lupus treatment Lupuzor to market. The company confirmed it was in the final stages of rolling out its managed access program to eligible patients in Europe.

'As part of this strategy, the company continues to engage with potential corporate partners as well as commencing a Managed Access Program for Lupuzor,' the company said.

The Lupuzor open label extension study, from the original Phase III trial, with a total of 62 eligible patients recruited throughout the US and Europe, remained on track to report results in Q2 2019.

The company also said talks on the clinical development collaboration with Incanthera Limited on the Nucant cancer programme were ongoing.

At 9:50am: [LON:IMM] ImmuPharma PLC share price was -1.27p at 11.48p

Story provided by